FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 359:2517-2519 December 11, 2008 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

More than 160,000 implantable cardioverter–defibrillators (ICDs) are implanted annually in the United States to prevent sudden death from cardiac causes in high-risk patients. Recently, concerns have been raised about the premarket testing of these life-saving devices.¹ At issue is how new ICD technologies should be evaluated before they are approved by the Food and Drug Administration (FDA) for general use. ICD manufacturers strive to develop devices that are smaller, easier to implant, and more attractive to patients, but they are reluctant to subject these innovations to premarket clinical testing because such trials are costly and may delay the introduction of . . . [Full Text of this Article]

Source Information

Dr. Hauser is a cardiologist and Dr. Almquist a clinical cardiac electrophysiologist at the Minneapolis Heart Institute, Minneapolis.

Related Letters:

Testing New ICD Technology
Shein M. J., Schultz D. G.
Extract | Full Text | PDF  
N Engl J Med 2008; 359:2610, Dec 11, 2008. Correspondence

This article has been cited by other articles:

• Shein, M. J., Schultz, D. G. (2008). Testing New ICD Technology. NEJM 359: 2610-2610 [Full Text]